Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia.
about
Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines.Interleukin-8 production by human airway epithelial cells in response to Pseudomonas aeruginosa clinical isolates expressing type a or type b flagellins.Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-induced pneumonia in the immunocompetent rat.The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem.Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate).Clearance of Pseudomonas aeruginosa from the murine gastrointestinal tract is effectively mediated by O-antigen-specific circulating antibodiesPseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia.Recent developments for Pseudomonas vaccines.Effect of antiflagellar human monoclonal antibody on gut-derived Pseudomonas aeruginosa sepsis in miceActivated β2 Integrins Restrict Neutrophil Recruitment during Murine Acute Pseudomonal Pneumonia.Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection.Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
P2860
Q33613907-CD152BF8-8F06-4EA8-842F-45B2611E471CQ34044986-CD2EABDD-46CB-4A9A-91E0-300A6C479E2DQ34543905-116E9153-7369-4C6C-A776-F92A3EED9B94Q34984415-98DFF90C-DABB-4D8A-A1F9-40CAD11EB7B9Q35377220-202B06B2-995E-42CE-B6A5-C013840A4102Q35426022-B1E3BFD9-62FD-488E-A94C-5718A7B382D2Q36013525-0723B6CF-CD6E-410F-8F3E-8DEF7238188EQ37451128-D247C3B8-4E94-46CC-95DD-1FE84B7953BAQ37937369-2E9CD464-6170-4C9B-8BFA-BC96B9503F40Q39506398-CF794312-FD3D-41F5-8FA0-D866FBC82C1DQ40347084-87606C66-F3FC-4E1A-BEF3-66C7EC4E0571Q44121558-D4C0DAA4-B2F3-4241-9D4E-B8AC78B65ADAQ45980499-3F754187-ADB1-4B12-9DAE-F6C74E1BA015
P2860
Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Therapeutic effects of a human ...... udomonas aeruginosa pneumonia.
@ast
Therapeutic effects of a human ...... udomonas aeruginosa pneumonia.
@en
type
label
Therapeutic effects of a human ...... udomonas aeruginosa pneumonia.
@ast
Therapeutic effects of a human ...... udomonas aeruginosa pneumonia.
@en
prefLabel
Therapeutic effects of a human ...... udomonas aeruginosa pneumonia.
@ast
Therapeutic effects of a human ...... udomonas aeruginosa pneumonia.
@en
P2093
P2860
P356
P1476
Therapeutic effects of a human ...... udomonas aeruginosa pneumonia.
@en
P2093
K Matsumoto
K Watanabe
P Ponglertnapagorn
T Nagatake
P2860
P304
P356
10.1128/AAC.37.2.164
P407
P577
1993-02-01T00:00:00Z